Published in Cancer Weekly, September 4th, 1995
The availability of recombinant human Epo has decreased the need for transfusion therapy of anemia (with its attendant dangers). A report by Spivak et al. (Hematology/Oncology Clinics of N. America, 1994;8(5):863-1043) noted that treatment with recombinant human Epo, given two to three times weekly, raised hemoglobin and hematocrit levels and improved cardiovascular status in the patients who received it.
William R.A. Osborne et al. reflected that the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.